SCHEMBL23851980

SCHEMBL23851980

N#Cc1ccc(N2CCC(F)CC2)c(N)c1

nearest known ligand 0.41

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
GAA P10253 3/20 0.41
MEN1 O00255 1/20 0.41
USP2 O75604 1/20 0.41
KMT2A Q03164 1/20 0.41
ALDH1A1 P00352 7/20 0.41
HTT P42858 3/20 0.41
KDM4E B2RXH2 6/20 0.40
POLB P06746 1/20 0.40
NR4A1 P22736 1/20 0.40
HSD17B10 Q99714 1/20 0.40
LRRK2 Q5S007 1/20 0.40
SMN1; SMN2 Q16637 2/20 0.40
MAPT P10636 2/20 0.40
LMNA P02545 2/20 0.40
L3MBTL1 Q9Y468 1/20 0.40
S100B P04271 1/20 0.39
DPP4 P27487 1/20 0.39
NPC1 O15118 1/20 0.38
HPGD P15428 1/20 0.38
RAB9A P51151 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL31588227 1.00 GAA (0.41) GAAMEN1USP2KMT2AALDH1A1
SCHEMBL31587487 0.86 KDM4E (0.47) GAAMEN1USP2KMT2AALDH1A1
SCHEMBL26143861 0.86 KDM4E (0.56) GAAMEN1USP2KMT2AALDH1A1
SCHEMBL23850705 0.86 KDM4E (0.47) GAAMEN1USP2KMT2AALDH1A1
SCHEMBL23850784 0.84 HTT (0.47) GAAALDH1A1HTTKDM4ELRRK2
SCHEMBL23850786 0.84 HTT (0.47) GAAALDH1A1HTTKDM4ELRRK2
SCHEMBL31587376 0.84 HTT (0.47) GAAALDH1A1HTTKDM4ELRRK2
SCHEMBL31738557 0.84 HTT (0.47) GAAALDH1A1HTTKDM4ELRRK2
SCHEMBL9424288 0.83 ALDH1A1 (0.55) GAAMEN1KMT2AALDH1A1KDM4E
SCHEMBL28799312 0.82 TNIK (0.44) GAAMEN1USP2KMT2AALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-12485169-B2 Compounds Grey Wolf Therapeutics Limited (GB) 2025-12-02 US disclosed
US-20230064417-A1 COMPOUNDS Grey Wolf Therapeutics Limited (GB) 2023-03-02 US disclosed
EP-3883650-A1 COMPOUNDS Grey Wolf Therapeutics Limited (GB) 2021-09-29 EP disclosed
CN-113056305-A Compound (I) 格雷沃尔夫治疗有限公司 2021-06-29 CN disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20230064417-A1 COMPOUNDS H4C1; H4C2; H4C3; H4C4; H4C5; H4C6; H4C8; H4C9; H4C11; H4C12; H4C13; H4C14; H4C15; H4C16, HRH4, CBR3 GAA 3530/4885MEN1 1332/4885USP2 3584/4885
US-12485169-B2 Compounds SLC10A1, VHL, CFTR GAA 96/4885MEN1 161/4885USP2 3954/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.